The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
RESORCE: An ongoing randomized, double-blind, phase III trial of regorafenib (REG) in patients with hepatocellular carcinoma (HCC) progressing on sorafenib (SOR).
Jordi Bruix
Consultant or Advisory Role - ArQule; Bayer; Biocompatibles; Bristol-Myers Squibb; Daiichi Sankyo; Novartis; Roche
Honoraria - Bayer; Biocompatibles; Bristol-Myers Squibb; Novartis
Research Funding - ArQule; Bayer; Daiichi Sankyo
Richard S. Finn
Consultant or Advisory Role - Bayer; Bristol-Myers Squibb; Onyx
Masatoshi Kudo
No relevant relationships to disclose
Josep M. Llovet
Consultant or Advisory Role - Bayer; BioSphere Medical; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; NanoString Technologies
Honoraria - Bayer; Bristol-Myers Squibb; Lilly; NanoString Technologies
Research Funding - Bayer; Boehringer Ingelheim
Shukui Qin
No relevant relationships to disclose
Marie-Aude Le Berre
Employment or Leadership Position - Bayer
Andrea Wagner
Employment or Leadership Position - Bayer
Ann-Lii Cheng
Consultant or Advisory Role - Boehringer Ingelheim Taiwan Ltd